Emoks of Of

General characteristics. Structure:

Active ingredient: 10 mg of a metiletilpiridinol of a hydrochloride in 1 ml of solution.

Excipients: 0,1 M acid solution hydrochloric, water for injections.

Pharmacological properties:

Pharmacodynamics. Metiletilpiridinol exerts beneficial effect on system of a blood coagulation: slows down aggregation of thrombocytes, reduces the general index of coagulation, extends a blood clotting time. Strengthens process of a fibrinolysis. Reduces viscosity of blood, permeability of a vascular wall. Stabilizes membranes of cells of blood vessels and erythrocytes, increases resistance of erythrocytes to a mechanical injury and hemolysis. Has angioprotektorny properties. Improves microcirculation. Effectively inhibits free radical oxidation of lipids of biomembranes, increases activity of antioxidant enzymes. Stabilizes R-450 cytochrome, possesses anti-toxic action. In the extreme situations which are followed by strengthening of peroxide oxidation of lipids and a hypoxia optimizes biopower processes.

Medicine protects an eye retina from the damaging effect of light of high intensity, promotes a rassasyvaniye of intraocular hemorrhages.

Promotes regulation of oxidation-reduction system at a circulatory unefficiency. It is effective at the states which are followed by strengthening of peroxide oxidation of lipids.

Pharmacokinetics. At intravenous administration in a dose of 10 mg/kg the elimination half-life makes 18 minutes; the general clearance – 0,2 l/minute; distribution volume – 5,2 l. Drug quickly gets into bodies and fabrics where there is its deposition and metabolism. 5 metabolites of a metiletilpiridinol presented by the dialkylated and conjugated products of its transformation are revealed. Metabolites of a metiletilpiridinol are excreted by kidneys. In significant amounts in a liver 2-ethyl-6-methyl-3-oxypyridinphosphate is found.

At retrobulbar introduction метилэтилпиридинол almost instantly appears in blood; within the first two hours its concentration sharply decreases and in 24 hours drug in blood is absent. In eye tissues concentration of a metiletilpiridinol is higher, than in blood serum.

Indications to use:

In ophthalmology:

· central chorioretinal dystrophies;

· dystrophic changes of a retina at a myopia of high degree;

· diabetic retinopathy;

· occlusions of the central vein of a retina and its branches;

· glaucoma (in the postoperative period);

· optikoneyropatiya of various genesis;

· hemophthalmias, hyphemas, keratitis, keratoconus, uveites;

· protection of a cornea (when carrying contact lenses) and protection of a mesh cover of an eye at influence of light of high intensity (laser and sunblisters, a lazerokoagulyation);

· injury, inflammation and burn of a cornea;

· a cataract (including prevention at persons is more senior than 40 years);

· operative measures in the eyes;

· a state after operation for glaucoma with choroid amotio.

In surgery:

· acute pancreatitis (when performing low-invasive interventions under OUSE control and laparoscopies).

Route of administration and doses:

Doses, duration of a course of treatment are defined individually.

In ophthalmology at patients with the central chorioretinal dystrophies, dystrophic changes of a retina at a myopia of high degree, at a diabetic retinopathy, occlusions of the central vein of a retina and its branches, glaucoma, optikoneyropatiya appoint retrobulbarno (parabulbarno) on 0,5 – 1 ml of solution 10 mg/ml of 1 times a day within 10 – 15 days (a course dose at damage of one eye – 100 – 150 mg, at bilateral defeat – 200 – 300 mg). At hyphemas, a keratitis, a keratoconus, uveites appoint subkonjyunktivalno on 0,2 – 0,5 ml of solution 10 mg/ml of 1 times a day within 10 – 15 days. If necessary duration of treatment can proceed up to 30 days. Repetition of a course 2 – 3 times a year is possible.

For protection of a retina at a lazerokoagulyation (including at the limiting and destroying coagulation of tumors) – parabulbarno or retrobulbarno on 0,5 – 1 ml of solution of 10 mg/ml for 24 h and for 1 h before coagulation; then – in the same doses (on 0,5 ml of solution of 10 mg/ml) 1 time a day within 2 – 10 days.

In surgery: at patients with acute pancreatitis when performing low-invasive interventions under OUSE by control and laparoscopies apply as follows: 10 ml of solution of 10 mg/ml of a metiletilpiridinol part in the syringe from 10 ml of solution of sodium of chloride isotonic and evenly infiltrut parapancreatic cellulose and an omental bursa, and also enter into cavities after aspiration of pancreatic accumulation of liquid.

Features of use:

It is necessary to control constantly during treatment the arterial pressure and coagulability of blood.

Medicine does not influence ability to manage vehicles and the machine equipment.

Side effects:

As a rule, adverse effects at use of drug are not observed.

In some cases perhaps short-term excitement, drowsiness, increase in arterial pressure, allergic reactions (skin rashes and others), local reactions – pain, burning, an itch, a hyperemia, consolidation of paraorbital fabrics (resolves independently).

Interaction with other medicines:

α-tocopherol acetate exponentiates antioxidant effect of a metiletilpiridinol.

Metiletilpiridinol is not recommended to mix with other injection means in one syringe.

Contraindications:

Hypersensitivity, pregnancy.

With care: the lactation period (according to indications).

Overdose:

At overdose strengthening of expressiveness of side effects of drug is possible.

Symptoms: increase in arterial pressure, excitement or drowsiness, a headache, pain in heart, nausea, discomfort in epigastric area. Disturbance of coagulability of blood is possible.

Treatment: drug withdrawal, performing symptomatic therapy, a specific antidote is not present.

Storage conditions:

In the place protected from light, at a temperature not over 30 ºС. To store in the place, unavailable to children. A period of validity - 2 years. Medicine cannot be used after the term specified on the label.

Issue conditions:

According to the recipe

Packaging:

In ampoules on 1 ml. On 10 ampoules together with a leaf insert place in a box from a cardboard; on 10 ampoules in the blister from a PVC film, on 1 blister together with a leaf insert place in a pack from a cardboard; on 10 ampoules together with a leaf insert place in a pack from a cardboard.